Use: Labeled indications
- The relief of symptoms associated with perennial allergic rhinitis
- The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
Full indications and usage US FDA label
1 INDICATIONS AND USAGE XYZAL is a histamine H 1 -receptor antagonist indicated for: The relief of symptoms associated with perennial allergic rhinitis (1.1) The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.2) 1.1 Perennial Allergic Rhinitis XYZAL is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. 1.2 Chronic Idiopathic Urticaria XYZAL is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.
Contraindications
4 CONTRAINDICATIONS The use of XYZAL is contraindicated in: Patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL or to cetirizine (4.1) Patients with end-stage renal disease at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis (4.2) Children 6 months to 11 years of age with renal impairment (4.3) 4.1 Patients with Known Hypersensitivity Patients with known hypersensitivity to levocetirizine or any of the ingredients of XYZAL, or to cetirizine. Observed reactions range from urticaria to anaphylaxis [see Adverse Reactions (6.2)]. 4.2 Patients with End-Stage Renal Disease Patients with end-stage renal disease (CL CR <10 mL/min) and patients undergoing hemodialysis 4.3 Pediatric Patients with Impaired Renal Function Children 6 months to 11 years of age with impaired renal function
US FDA labelDosing: Adult
- XYZAL is available as 2.5 mg/5 mL (0.5 mg/mL) oral solution and as 5 mg breakable (scored) tablets, allowing for the administration of 2.5 mg, if needed. XYZAL can be taken without regard to food consumption. Perennial Allergic Rhinitis (2.1)
- Children 6 months to 2 years of age: 1.25 mg (1/2 teaspoon oral solution) (2.5 mL) once daily in the evening Chronic Idiopathic Urticaria (2.2)
- Adults and children 12 years of age and older: 5 mg once daily in the evening Children 6 to 11 years of age: 2.5 mg once daily in the evening Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) (2.5 mL) once daily in the evening Renal Impairment Adjust the dose in patients 12 years of age and older with decreased renal function (12.3)
2.1 Perennial Allergic Rhinitis
2.1 Perennial Allergic Rhinitis Children 6 months to 2 Years of Age The recommended initial dose of XYZAL is 1.25 mg (1/2 teaspoon oral solution) (2.5 mL) once daily in the evening. The 1.25 mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5 mg [see Clinical Pharmacology (12.3)].
2.2 Chronic Idiopathic Urticaria Adults and Children 12 Years of Age and Older
2.2 Chronic Idiopathic Urticaria Adults and Children 12 Years of Age and Older The recommended dose of XYZAL is 5 mg (1 tablet or 2 teaspoons [10 mL] oral solution) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (1/2 tablet or 1 teaspoon [5 mL] oral solution) once daily in the evening. Children 6 to 11 Years of Age The recommended dose of XYZAL is 2.5 mg (1/2 tablet or 1 teaspoon [5 mL] oral solution) once daily in the evening.
The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults [see Clinical Pharmacology (12.3)]. Children 6 months to 5 Years of Age The recommended initial dose of XYZAL is 1.25 mg (1/2 teaspoon oral solution) (2.5 mL) once daily in the evening. The 1.25 mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5 mg [see Clinical Pharmacology (12.3)].
Dose Adjustment for Renal and Hepatic Impairment In adults and children 12 years of age and older with: Mild renal impairment (creatinine clearance [CL CR] = 50-80 mL/min): a dose of 2.5 mg once daily is recommended; Moderate renal impairment (CL CR = 30-50 mL/min): a dose of 2.5 mg once every other day is recommended; Severe renal impairment (CL CR = 10-30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3-4 days) is recommended; End-stage renal disease patients (CL CR <10 mL/min) and patients undergoing hemodialysis should not receive XYZAL. No dose adjustment is needed in patients with solely hepatic impairment.
In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.
Dosing: Altered kidney function
8.6 Renal Impairment XYZAL is known to be substantially excreted by the kidneys and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function [see Dosage and Administration (2) and Clinical Pharmacology (12.3)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment As levocetirizine is mainly excreted unchanged by the kidneys, it is unlikely that the clearance of levocetirizine is significantly decreased in patients with solely hepatic impairment [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The recommended dose of XYZAL for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in patients 6 months to 17 years of age is based on extrapolation of efficacy from adults 18 years of age and older [see Clinical Studies (14)]. The recommended dose of XYZAL in patients 6 months to 2 years of age for the treatment of the symptoms of perennial allergic rhinitis and 6 months to 11 years of age with chronic idiopathic urticaria is based on cross-study comparisons of the systemic exposure of XYZAL in adults and pediatric patients and on the safety profile of XYZAL in both adult and pediatric patients at doses equal to or higher than the recommended dose for patients 6 months to 11 years of age.
The safety of XYZAL 5 mg once daily was evaluated in 243 pediatric patients 6 to 12 years of age in two placebo-controlled clinical trials lasting 4 and 6 weeks. The safety of XYZAL 1.25 mg twice daily was evaluated in one 2-week clinical trial in 114 pediatric patients 1 to 5 years of age and the safety of XYZAL 1.25 mg once daily was evaluated in one 2-week clinical trial in 45 pediatric patients 6 to 11 months of age [see Adverse Reactions (6.1)].
The effectiveness of XYZAL 1.25 mg once daily (6 months to 5 years of age) and 2.5 mg once daily (6 to 11 years of age) for the treatment of the symptoms of perennial allergic rhinitis and chronic idiopathic urticaria is supported by the extrapolation of demonstrated efficacy of XYZAL 5 mg once daily in patients 12 years of age and older based on the pharmacokinetic comparison between adults and children. Cross-study comparisons indicate that administration of a 5 mg dose of XYZAL to 6 to 12 year old pediatric patients resulted in about 2-fold the systemic exposure (AUC) observed when 5 mg of XYZAL was administered to healthy adults.
Therefore, in children 6 to 11 years of age the recommended dose of 2.5 mg once daily should not be exceeded. In a population pharmacokinetics study the administration of 1.25 mg once daily in children 6 months to 5 years of age resulted in systemic exposure comparable to 5 mg once daily in adults. [see Dosage and Administration (2.2), Clinical Studies (14), and Clinical Pharmacology (12.3)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of XYZAL for each approved indication did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
Dosage forms
Philippines
- Film-coated tablet: 5 mg, 10 mg
- Syrup: 2.5 mg/5 mL, 2.5 mg/mL, 5 mg/mL, 500 mcg/mL
- Tablet: 5 mg
- Oral solution: 500 mcg/mL
- Orally disintegrating tablet: 5 mg
- Orally disinegrating tablet: 5 mg
- Syrup syrup: 2.5 mg/5 mL
Registered products in the Philippines
81 products registered with the Food and Drug Administration (FDA) Philippines list Levocetirizine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Levocetrizine dihyrdrochloride (1 product). Products registered under these spellings are included in the table and marked.
All registered products81
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlerixLevocetirizine Dihydrochloride | 2.5 mg / 5 mL Syrup60 mL, 120mL and 250 mL PET Round Amber Bottle with HDPE Cap [Box of 1's] | Rx | Enicar Pharmaceuticals Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13608-02 | Mar 17, 2028 | |
AllecureLevocetirizine Dihydrochloride | 5 mg Film Coated TabletAlu / PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., IncPhilippines | — | DRP-8954 | Aug 27, 2030 | |
ALLERGOSTOPLevocetirizine Dihydrochloride | 5mg TabletAlu-PVDC blister pack of 10's | Rx | Simpex Pharma Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corporation | DRP-1172 | Apr 27, 2027 | |
AllerichLevocetirizine dihydrochloride | 5 mg TabletAlu/White PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Healer's Lab (Unit II)India | Medirich Pharma Distribution Corp.Importer: Pharmakon Biotec Inc. | DRP-10220-03 | Oct 1, 2031 | |
AllervocinLevocetirizine dihydrochloride | 2.5 mg/ 5 mL SyrupPET amber coloured bottle x 100 mL with 10 mL measuring cup (Box of 1’s) | Rx | Medley Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-9723 | May 12, 2031 | |
AllerzetLevocetirizine dihydrochloride | 2.5 mg/5 mL SyrupAmber glass bottle (in a box) of 30mL, 60mL and 120mL with Type III, Pilfer proof (PP) finish, Aluminum, white-colored cap with Sureseal 226 liner | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY37865 | Oct 3, 2027 | |
AllerzetLevocetirizine dihydrochloride | 2.5 mg/5 mL SyrupAmber glass bottle (in a box) of 30mL, 60mL, and 120mL with Type III, Pilfer proof (PP) finish, Aluminum, white colored cap with Sureseal 226 liner | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-13912 | Oct 3, 2027 | |
5 mg Film-Coated TabletAlu/Alu blister pack x 10's Box of 100's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY36974 | Sep 19, 2027 | ||
AllerzineLevocetirizine (as Hydrochloride) | 500mcg/mL Syrup60 mL amber glass bottle (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-13121 | Dec 2, 2027 | |
AlzetLevocetirizine dihydrochloride | 5 mg TabletAlu/White PVC Blister Pack x 10's (Box of 30's) | Rx | Healer's Lab (Unit II)India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-10220-01 | Oct 1, 2031 | |
AmkohistLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Amk Pharma International TradingImporter: Ambica International Corporation | DRP-4501-03 | Jun 28, 2028 | |
CenzetLevocetirizine Dihydrochloride | 2.5 mg/5 mL Syrup (Grapes Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL & 60 mL (Box of 1's) | Rx | LifeSquare Laboratories, Inc.Philippines | — | DRP-8766 | Mar 12, 2031 | |
CenzetLevocetirizine dihydrochloride | 2.5 mg/5 mL Syrup (Strawberry-Banana Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL (Box of 1's); Boston Round Amber Bottle with Aluminum Cap x 60 mL (Box of 1's) | Rx | LifeSquare Laboratories, Inc.Philippines | — | DRP-8767 | Mar 13, 2030 | |
CenzetLevocetirizine Dihydrochloride | 5 mg / mL Syrup (Oral Drops) (Grapes Flavor)Amber Glass Bottle w/ Aluminum Cap 15 mL (Box of 1's) | Rx | LifeSquare Laboratories Inc.Philippines | — | DRP-9577 | Mar 4, 2031 | |
CetaloreLevocetirizine Dihydrochloride | 5mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | KLM Laboratories Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-13130 | Dec 5, 2027 | |
CoalbiLevocetirizine Hydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Aju Pharm Co., Ltd.Republic of Korea | Jazmark Pharmaceutical | DRP-6862 | Aug 19, 2029 | |
ColbLevocetirizine Hydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Daewon Pharm. Co., Ltd.Republic of Korea | Jazmark PharmaceuticalImporter: H & B Pharma International Inc. | DRP-5005-01 | Dec 10, 2028 | |
DirocetLevocetirizine Dihydrochloride | 2.5 mg/5 mL SyrupAmber colored PET Bottle x 30 mL (Box of 1's); Amber colored PET Bottle x 60 mL (Box of 1's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Pharmastar Int'l Trading Corp. | DRP-9920 | May 6, 2029 | |
GicetirLevocetirizine Dihydrochloride | 5 mg Film-Coated Tablet | Rx | Agio Pharmaceuticals Ltd. | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3806-01 | Dec 1, 2026 | |
GlencetLevocetirizine Hydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's) | Rx | Glenmark Pharmaceutical LimitedIndia | Glenmark Philippines, Inc. | DRP-6884 | Nov 3, 2031 | |
Hicet-LLevocetirizine Hydrochloride | 5mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Micro Labs LimitedIndia | Brown & burk Philippines, Inc.Importer: Brown & Burk Philippines, Inc. | DR-XY40393 | Dec 8, 2031 | |
HistalevLevocetirizine hydrochloride | 5 mg Film - Coated TabletAlu/PVC Blister Pack x 10's Box of 30's | Rx | Zim Laboratories LimitedIndia | Suhitas Pharmaceuticals Inc.Trader: Amegh Pharma Pvt. Ltd. | DRP-3935 | Sep 4, 2027 | |
IztaidLevocetirizine Hydrochloride | 2.5mg/5mL SyrupBoston round glass amber bottle x 60 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-14875 | Jan 30, 2029 | |
IztaidLevocetirizine Hydrochloride | 5mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's, and 100's) | Rx | Azarias Pharmaceutical Laboratories IncPhilippines | — | DRP-14876 | Jan 30, 2029 | |
KaicerineLevocetirizine Hydrochloride | 2.5 mg/5 mL SyrupPolyethylene Terephthalate (PET) Amber Bottle Sealed with Polypropylene Cap x 60 mL with 10 mL Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Kaiv Pharmaceutical Product DistributionImporter: Ambica International Corporation | DRP-8838-02 | Jul 2, 2030 | |
L-TrizineLevocetirizine Dihydrochloride | 5 mg TabletAlu/Alu Blister pack x 10's (Box of 100's) | Rx | Medchem International LimitedIndia | Pharma-Surrey International, Inc. | DRP-4158 | Dec 18, 2027 | |
L-ZinexLevocetirizine hydrochloride | 2.5 mg/5 mL SyrupRound Amber PET Bottle x 30 mL (Box of 1's) | Rx | Corona Remedies Pvt. Ltd.India | Iberica Verheilen Pharmaceuticals Group Corp.Importer: Verheilen Iberica Health Care Company Inc.Trader: Farma Iberica SL | DR-XY46352 | May 30, 2028 | |
LczinLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Greencore Pharma Inc. | DRP-9090 | Jan 7, 2030 | |
LecerinLevocetirizine hydrochloride | 500 mcg/mL Syrup75 mL (net content) in 80mL Clear PET Bottle (Box of 1’s) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP-14548 | Aug 28, 2030 | |
LecetrizLevocetirizine Hydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | East African (India) OverseasIndia | Airlife International Trading Corporation | DRP-17226 | Oct 23, 2030 | |
LecetzyLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Zee LaboratoriesIndia | Eon Pharmatek Inc. | DR-XY43715 | Sep 5, 2029 | |
Levance 5Levocetirizine Dihydrochloride | 5 mg Film Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4497 | Jun 25, 2028 | |
LevizineLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DRP-6065 | Nov 7, 2028 | |
LevocecLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-12177 | Jun 29, 2027 | |
LevocemaxLevocetirizine hydrochloride | 5 mg TabletAlu/PVDC blister pack x 10's (Box of 10 tablets) | Rx | Simpex Pharma Pvt. Ltd.India | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-11772-01 | Apr 27, 2027 | |
LevocerLevocetirizine hydrochloride | 10 mg Film-coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Aurochem Pharmaceutical (India) Pvt. Ltd.India | Endure Medical, Inc. | DR-XY43987 | Dec 15, 2029 | |
LevocerLevocetirizine Hydrochloride | 5 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | AUROCHEM PHARMACEUTICAL (I) PVT. LTD.India | ENDURE MEDICAL, INC. | DR-XY43331 | Apr 1, 2029 | |
LevocitLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's and 100's) | Rx | Brookes Pharma (Private) LimitedPakistan | Sahar International Trading, Inc. | DR-XY44237 | Feb 25, 2030 | |
LevollenLevocetirizine dihydrochloride | 2.5 mg/5 mL Syrup Syrup60 mL, 120 mL and 250 mL PET Round Amber Bottle with HDPE Cap (Box of 1’s) | Rx | Enicar Pharmaceuticals Pvt. Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13608-01 | Mar 17, 2028 | |
LevorideLevocetirizine dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | Rx | Oman Pharmaceutical Products Co., LLCOman | Madecs Pharma CorporationImporter: Atlantic Pharmaceuticals, Inc. | DR-XY43579 | Jul 31, 2029 | |
LevorinLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY44122 | Feb 2, 2030 | |
LevorizLevocetirizine hydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Pharmatec Pakistan (Pvt.) Ltd.Pakistan | Sahar International Trading Inc. | DR-XY42331 | Jul 29, 2028 | |
LevosaphzineLevocetirizine dihydrochloride. | 2.5 mg/5 mL SyrupPET Round Amber Bottle with White HDPE Plastic Cap (Each box of 60 mL; 120 mL; 250 mL) | Rx | Azine Healthcare Pvt. Ltd.India | Ollen Pharma Trading Inc.Trader: Sapphire Life Sciences Pvt. | DRP-14817 | Jan 16, 2029 | |
Levosaphzine-5Levocetirizine dihydrochloride | 2.5mg/5mL Syrup60 mL, 120 mL and 250 mL PET Round Amber Bottle with HDPE Cap [Box of 1's] | Rx | Enicar Pharmaceuticals Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13608 | Mar 17, 2028 | |
LevothixLevocetirizine Dihydrochloride | 5 mg Orally Disintegrating TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Athena Drug Delivery Solutions Pvt. Ltd.India | MedEthix, Inc. | DRP-11785 | Jul 15, 2027 | |
LevozartLevocetirizine dihydrochloride | 5 mg TabletAlu/White PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Healer's Lab (Unit II)India | Pharmakon Biotec Inc. | DRP-10220 | Oct 1, 2031 | |
LevozinLevocetirizine Hydrochloride | 5 mg Orally Disinegrating TabletAlu/Alu Blister pack x 10's (Box of 100's) | Rx | Athena Drug Delivery Solutions Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutal Inc. | DRP-11273-0 | Feb 22, 2027 | |
LevozyrLevocetirizine | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | GENUONE Sciences Inc.Republic of Korea | JustRight Healthcare Inc. | DR-XY42702 | Sep 30, 2028 | |
LevzelLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s, 60’s and 100’s) | Rx | West Coast Pharmaceutical Works Ltd.India | Despina Pharma Inc. | DRP-19161 | Nov 11, 2031 | |
LevzineLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generish Trading Inc. | DRP-14876-02 | Jan 30, 2029 | |
Levzine SLevocetirizine Dihydrochloride | 2.5 mg/ 5 mL SyrupBoston round glass amber bottle x 60 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-14875-02 | Jan 30, 2029 | |
LezyncetLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's) | Rx | Zim Laboratories Ltd.India | Ambica International CorporationTrader: Rainbow Life Science Pvt. Ltd. | DRP-3058 | Jun 16, 2031 | |
LisinexLevocetirizine (as Dihydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International CorporatioImporter: Ambica International Corporation | DRP-2221 | Jun 3, 2032 | |
LocetinLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Scott-Edil Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-5949 | Jan 21, 2030 | |
NoneLevocetirizine hydrochloride | 2.5 mg/5 mL SyrupPolyethylene Terephthalate (PET) Amber Bottle Sealed with Polypropylene Cap x 60 mL with 10 mL Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-8838-04 | Jul 2, 2030 | |
NoneLevocetirizine hydrochloride | 2.5 mg/mL SyrupAmber Glass Bottle with Aluminum Pilfer-Proof Cap x 30 mL and 60 mL (Box of 1's) | Rx | Amherst Laboratories, Inc.Philippines | — | DRP-9631 | Apr 16, 2031 | |
NoneLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletClear PVC/Alu Blister Pack x 50's (Box of 50's) | Rx | Ind-Swift LimitedIndia | RiteMED Phils., Inc. | DR-XY38458 | Sep 2, 2027 | |
NoneLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-4501-02 | Jun 28, 2028 | |
NovacetrinLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Foil Strip Pack x 10's (Box of 10's & 100's) | Rx | Acme Formulation Pvt. Ltd.India | Importer: Medinova Pharmaceutical, Inc. | DRP-11251 | Feb 17, 2027 | |
NovazineLevocetirizine hydrochloride | 5 mg Orally Disintegrating TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Athena Drug Delivery Solutions Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-11273 | Feb 22, 2027 | |
PhilcetLevocetirizine | 5 mg Film-Coated TabletAlu/PVC Blister x 10’s (Box of 100’s) | Rx | Agio Pharmaceuticals LimitedIndia | Bell-Kenz Pharma Inc.Importer: Ambica International Corporation | DRP-3806-04 | Oct 31, 2037 | |
RelizetLevocetirizine Dihydrochloride | 5mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY37391 | Jan 21, 2030 | |
SensitrinLevocetirizine Hydrochloride | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Daewon Pharm. Co., Ltd.Korea | Littman Drug CorporationImporter: H & B Pharma International Inc. | DRP-5005 | Dec 10, 2028 | |
StalevoLevocetirizine hydrochloride | 2.5 mg/5 mL SyrupPolyethylene Terephthalate (PET) Amber Bottle Sealed with Polypropylene Cap x 60 mL with 10 mL Measuring Cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Maed Pharma CorporationImporter: Ambica International Corporation | DRP-8838 | Jul 2, 2030 | |
Stalevo-5Levocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | GPC Geo Pharma CorporationImporter: Ambica International Corporation | DRP-4501 | Jun 28, 2028 | |
TrezinLevocetirizine dihydrochloride | 2.5 mg/5 mL Syrup (Strawberry-Banana Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL & 60 mL (Box of 1's) | Rx | LifeSquare Laboratories, Inc.Philippines | Alman Pharmaceuticals, Inc. | DRP-8767-03 | Mar 6, 2031 | |
UnbrandedLevocetirizine | 5 mg Film-Coated Tablet | Rx | Agio Pharmaceuticals Limited | — | DRP-3806-02 | Dec 1, 2026 | |
UnbrandedLevocetirizine | 5 mg Film-Coated Tablet | Rx | Agio Pharmaceuticals Limited | — | DRP-3806-03 | Dec 1, 2026 | |
VelozetLevocetirizine dihydrochloride | 2.5 mg/5 mL Syrup (Strawberry-Banana Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL and 60 mL (Box of 1's) | Rx | LifeSquare Laboratories, Inc.Philippines | Korn C Philippines Inc. | DRP-8767-02 | Feb 20, 2031 | |
VeltirLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-4501-01 | Jun 28, 2028 | |
XyzalLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's. (Box of 30's) | Rx | UCB Farchim SASwitzerland | GlaxoSmithKline Philippines, Inc. | DR-XY28008 | Oct 31, 2031 | |
XyzalLevocetirizine Dihydrochloride | 500 mcg/mL Oral SolutionType III Amber Glass Bottle with Plastic Child Resistant Cap x 75 mL (Box of 1's) | Rx | Aesica Pharmaceutical S.R.L.Italy | Importer: GlaxoSmithKline Philippines, Inc. | DR-XY37522 | Feb 19, 2030 | |
ZercinLevocetirizine dihydrochloride | 2.5 mg/5 mL Syrup (Strawberry-Banana Flavor)Boston Round Amber Bottle with Aluminum Cap x 30 mL & 60 mL (Box of 1's) | Rx | LifeSquare Laboratories, Inc.Philippines | Novomed Inc. | DRP-8767-01 | Feb 25, 2031 | |
ZestraLevocetirizine (as dihydrochloride) | 5 mg Film-Coated TabletAlu-Clear PVC Blister Pack x 10’s (Box of 60’s) | Rx | Schazoo Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Zuneca Incorporated | DRP-2411 | Aug 23, 2030 | |
ZetrinelLevocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-14876-01 | Jan 30, 2029 | |
Zetrinel-SLevocetirizine Hydrochloride | 2.5 mg/ 5 mL SyrupBoston round glass amber bottle x 60 mL (Box of 1's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-14875-01 | Jan 30, 2029 | |
Zocet 5Levocetirizine | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Agio Pharmaceuticals Ltd.India | PFC Drug Distributors Company Ltd.Importer: Ambica International Corporation | DRP-3806 | Dec 1, 2031 | |
ZyphrineLevocetirizine Hydrochloride | 2.5 mg/5 mL SyrupPolyethylene terephthalate (PET) amber bottle sealed with polypropylene cap x 60 mL with 10 mL measuring cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Ambica International Corporation | DRP-8838-01 | Jul 2, 2030 | |
ZyvosalLevocetirizine hydrochloride | 2.5 mg / 5 mL SyrupPolyethylene terephthalate (PET) amber bottle sealed with polypropylene cap x 60 mL with 10 mL measuring cup (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-8838-03 | Jul 2, 2030 | |
(no brand name)Levocetirizine Dihydrochloride | 5 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-12341 | Jul 20, 2027 | |
(no brand name)Levocetirizine dihydrochloride | 500 mcg/mL Oral SolutionUSP Type III Boston round amber coloured glass bottle with 20 mm foam-lined polyethylene lined with pressure sensitive polystyrene PP Aluminum cap x 30mL and 60mL (Box of 1's) | Rx | Sydenham Laboratories, IncPhilippines | — | DRP-17822 | Mar 16, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS XYZAL oral solution is a clear, colorless liquid containing 0.5 mg of levocetirizine dihydrochloride per mL. XYZAL tablets are white, film-coated, oval-shaped, scored, imprinted (with the letter Y in red color on both halves of the scored tablet) and contain 5 mg levocetirizine dihydrochloride. Immediate release breakable (scored) tablets, 5 mg (3) Immediate release oral solution, 2.5 mg per 5 mL (0.5 mg per mL) (3)
Warnings/Precautions
- Somnolence: Somnolence, fatigue, and asthenia have been reported with use of XYZAL in some patients in clinical trials. Avoid engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking XYZAL. Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (5.1)
- Urinary Retention: Urinary retention has been reported with use of XYZAL. Use with caution in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia). Discontinue XYZAL if urinary retention occurs. (5.2)
- Risk of New Onset Pruritus After Discontinuation of XYZAL: New onset pruritus within a few days after discontinuation of XYZAL has been reported, usually after long-term use (e.g., few months to years) of XYZAL. Symptoms may improve with restarting or tapering XYZAL (5.3).
5.1 Somnolence
5.1 Somnolence In clinical trials the occurrence of somnolence, fatigue, and asthenia has been reported in some patients under therapy with XYZAL. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness, and motor coordination such as operating machinery or driving a motor vehicle after ingestion of XYZAL.
Concurrent use of XYZAL with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur.
5.2 Urinary Retention
5.2 Urinary Retention Urinary retention has been reported post marketing with XYZAL. XYZAL should be used with caution in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as XYZAL may increase the risk of urinary retention. Discontinue XYZAL if urinary retention occurs.
5.3 Risk of New Onset Pruritus After Discontinuation
5.3 Risk of New Onset Pruritus After Discontinuation of XYZAL Cases of pruritus after discontinuation of XYZAL have been reported in the postmarketing setting in patients where pruritus was not present before initiation of XYZAL. Pruritus occurred within a few days of discontinuing XYZAL among patients who used XYZAL long-term (e.g., few months to years).
Reported cases of pruritus were infrequent, but some were serious with patients experiencing widespread severe pruritus [See Adverse Reactions (6.2)]. If pruritus occurs after discontinuation of XYZAL, symptoms may improve with restarting or tapering XYZAL.
Drug interactions
In vitro data indicate that levocetirizine is unlikely to produce pharmacokinetic interactions through inhibition or induction of liver drug-metabolizing enzymes. No in vivo drug-drug interaction studies have been performed with levocetirizine. Drug interaction studies have been performed with racemic cetirizine.
7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and…
7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine Pharmacokinetic interaction studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole, and cimetidine. There was a small decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline.
It is possible that higher theophylline doses could have a greater effect.
7.2 Ritonavir
7.2 Ritonavir Ritonavir increased the plasma AUC of cetirizine by about 42% accompanied by an increase in half-life (53%) and a decrease in clearance (29%) of cetirizine. The disposition of ritonavir was not altered by concomitant cetirizine administration.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Dealkylation pathways are primarily mediated by CYP3A4 while aromatic oxidation involves multiple and/or unidentified CYP isoforms.
Levocetirizine at concentrations well above C max level achieved within the therapeutic dose ranges is not an inhibitor of CYP isoenzymes 1A2, 2C9, 2C19, 2A1, 2D6, 2E1, and 3A4, and is not an inducer of UGT1A or CYP isoenzymes 1A2, 2C9 and 3A4.
Adverse reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Somnolence [see Warnings and Precautions (5.1)] Urinary Retention [see Warnings and Precautions (5.2)] Risk of New Onset Pruritus After Discontinuation of XYZAL [see Warnings and Precautions (5.3)] The most common adverse reactions (rate ≥2% and > placebo) were somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis in subjects 12 years of age and older, and pyrexia, somnolence, cough, and epistaxis in children 6 to 12 years of age. In subjects 1 to 5 years of age, the most common adverse reactions (rate ≥2% and > placebo) were pyrexia, diarrhea, vomiting, and otitis media.
In subjects 6 to 11 months of age, the most common adverse reactions (rate ≥3% and > placebo) were diarrhea and constipation. (6.1). To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described below reflect exposure to XYZAL in 2708 patients with allergic rhinitis or chronic idiopathic urticaria in 14 controlled clinical trials of 1 week to 6 months duration.
The short-term (exposure up to 6 weeks) safety data for adults and adolescents are based upon eight clinical trials in which 1896 patients (825 males and 1071 females aged 12 years and older) were treated with XYZAL 2.5, 5, or 10 mg once daily in the evening. The short-term safety data from pediatric patients are based upon two clinical trials in which 243 children with allergic rhinitis (162 males and 81 females 6 to 12 years of age) were treated with XYZAL 5 mg once daily for 4 to 6 weeks, one clinical trial in which 114 children (65 males and 49 females 1 to 5 years of age) with allergic rhinitis or chronic idiopathic urticaria were treated with XYZAL 1.25 mg twice daily for 2 weeks, and one clinical trial in which 45 children (28 males and 17 females 6 to 11 months of age) with symptoms of allergic rhinitis or chronic urticaria were treated with XYZAL 1.25 mg once daily for 2 weeks.
The long-term (exposure of 4 or 6 months) safety data in adults and adolescents are based upon two clinical trials in which 428 patients (190 males and 238 females) with allergic rhinitis were exposed to treatment with XYZAL 5 mg once daily. Long term safety data are also available from an 18-month trial in 255 XYZAL-treated subjects 12-24 months of age.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice. Adults and Adolescents 12 years of Age and Older In studies up to 6 weeks in duration, the mean age of the adult and adolescent patients was 32 years, 44% of the patients were men and 56% were women, and the large majority (more than 90%) was Caucasian.
In these trials 43% and 42% of the subjects in the XYZAL 2.5 mg and 5 mg groups, respectively, had at least one adverse event compared to 43% in the placebo group. In placebo-controlled trials of 1-6 weeks in duration, the most common adverse reactions were somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis, and most were mild to moderate in intensity.
Somnolence with XYZAL showed dose ordering between tested doses of 2.5, 5 and 10 mg and was the most common adverse reaction leading to discontinuation (0.5%). Table 1 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 12 years and older exposed to XYZAL 2.5 mg or 5 mg in eight placebo-controlled clinical trials and that were more common with XYZAL than placebo.
Table 1: Adverse Reactions Reported in ≥2%* of Subjects Aged 12 Years and Older Exposed to XYZAL 2.5 mg or 5 mg Once Daily in Placebo-Controlled Clinical Trials 1-6 Weeks in Duration Adverse Reactions XYZAL 2.5 mg (n = 421) XYZAL 5 mg (n = 1070) Placebo (n = 912) Somnolence 22 (5%) 61 (6%) 16 (2%) Nasopharyngitis 25 (6%) 40 (4%) 28 (3%) Fatigue 5 (1%) 46 (4%) 20 (2%) Dry Mouth 12 (3%) 26 (2%) 11 (1%) Pharyngitis 10 (2%) 12 (1%) 9 (1%) * Rounded to the closest unit percentage Additional adverse reactions of medical significance observed at a higher incidence than in placebo in adults and adolescents aged 12 years and older exposed to XYZAL are syncope (0.2%) and weight increased (0.5%). Pediatric Patients 6 to 12 Years of Age A total of 243 pediatric patients 6 to 12 years of age received XYZAL 5 mg once daily in two short-term placebo controlled double-blind trials.
The mean age of the patients was 9.8 years, 79 (32%) were 6 to 8 years of age, and 50% were Caucasian. Table 2 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 6 to 12 years exposed to XYZAL 5 mg in placebo-controlled clinical trials and that were more common with XYZAL than placebo.
Table 2: Adverse Reactions Reported in ≥2%* of Subjects Aged 6-12 Years Exposed to XYZAL 5 mg Once Daily in Placebo-Controlled Clinical Trials 4 and 6 Weeks in Duration Adverse Reactions XYZAL 5 mg (n = 243) Placebo (n = 240) Pyrexia 10 (4%) 5 (2%) Cough 8 (3%) 2 (<1%) Somnolence 7 (3%) 1 (<1%) Epistaxis 6 (2%) 1 (<1%) * Rounded to the closest unit percentage Pediatric Patients 1 to 5 Years of Age A total of 114 pediatric patients 1 to 5 years of age received XYZAL 1.25 mg twice daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 3.8 years, 32% were 1 to 2 years of age, 71% were Caucasian and 18% were Black.
Table 3 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 1 to 5 years exposed to XYZAL 1.25 mg twice daily in the placebo-controlled safety trial and that were more common with XYZAL than placebo. Table 3: Adverse Reactions Reported in ≥2%* of Subjects Aged 1-5 Years Exposed to XYZAL 1.25 mg Twice Daily in a 2-Week Placebo-Controlled Clinical Trial Adverse Reactions XYZAL 1.25 mg Twice Daily (n = 114) Placebo (n = 59) Pyrexia 5 (4%) 1 (2%) Diarrhea 4 (4%) 2 (3%) Vomiting 4 (4%) 2 (3%) Otitis Media 3 (3%) 0 (0%) * Rounded to the closest unit percentage Pediatric Patients 6 to 11 Months of Age A total of 45 pediatric patients 6 to 11 months of age received XYZAL 1.25 mg once daily in a two week placebo-controlled double-blind safety trial.
The mean age of the patients was 9 months, 51% were Caucasian and 31% were Black. Adverse reactions that were reported in more than 1 subject (i.e. greater than or equal to 3% of subjects) aged 6 to 11 months exposed to XYZAL 1.25 mg once daily in the placebo-controlled safety trial and that were more common with XYZAL than placebo included diarrhea and constipation which were reported in 6 (13%) and 1 (4%) and 3 (7%) and 1 (4%) children in the XYZAL and placebo-treated groups, respectively.
Long-Term Clinical Trials Experience In two controlled clinical trials, 428 patients (190 males and 238 females) aged 12 years and older were treated with XYZAL 5 mg once daily for 4 or 6 months. The patient characteristics and the safety profile were similar to that seen in the short-term studies. Ten (2.3%) patients treated with XYZAL discontinued because of somnolence, fatigue or asthenia compared to 2 (<1%) in the placebo group.
There are no long term clinical trials in children below 12 years of age with allergic rhinitis or chronic idiopathic urticaria. Laboratory Test Abnormalities Elevations of blood bilirubin and transaminases were reported in <1% of patients in the clinical trials. The elevations were transient and did not lead to discontinuation in any patient.
6.2 Postmarketing Experience
6.2 Postmarketing Experience In addition to the adverse reactions reported during clinical trials and listed above, the following adverse reactions have also been identified during postapproval use of XYZAL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac disorders: palpitations, tachycardia Ear and labyrinth disorders: vertigo Eye disorders: blurred vision, visual disturbances Gastrointestinal disorders: nausea, vomiting General disorders and administration site conditions: edema Hepatobiliary disorders: hepatitis Immune system disorders: anaphylaxis and hypersensitivity Metabolism and nutrition disorders: increased appetite Musculoskeletal, connective tissues, and bone disorders: arthralgia, myalgia Nervous system disorders: dizziness, dysgeusia, febrile seizure, movement disorders (including dystonia and oculogyric crisis), paresthesia, seizure (reported in subjects with and without a known seizure disorder), tremor Psychiatric disorders: aggression and agitation, depression, hallucinations, insomnia, nightmare, suicidal ideation Renal and urinary disorders: dysuria, urinary retention Respiratory, thoracic, and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: angioedema, fixed drug eruption, pruritus, rash, urticaria, and new onset pruritus within a few days after discontinuation of XYZAL, usually after long-term use (e.g., few months to years) of XYZAL Besides these reactions reported under treatment with XYZAL, other potentially severe adverse reactions have been reported from the postmarketing experience with cetirizine. Since levocetirizine is the principal pharmacologically active component of cetirizine, one should take into account the fact that the following adverse reactions could also potentially occur under treatment with XYZAL.
Cardiac disorders: severe hypotension Gastrointestinal disorders: cholestasis Nervous system disorders: extrapyramidal symptoms, myoclonus, orofacial dyskinesia, tic Pregnancy, puerperium and perinatal conditions: stillbirth Renal and urinary disorders: glomerulonephritis Skin and subcutaneous tissue disorders: acute generalized exanthematous pustulosis (AGEP)
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reactions | XYZAL 2.5 mg (n = 421) | XYZAL 5 mg (n = 1070) | Placebo (n = 912) |
| Somnolence | 22 (5%) | 61 (6%) | 16 (2%) |
| Nasopharyngitis | 25 (6%) | 40 (4%) | 28 (3%) |
| Fatigue | 5 (1%) | 46 (4%) | 20 (2%) |
| Dry Mouth | 12 (3%) | 26 (2%) | 11 (1%) |
| Pharyngitis | 10 (2%) | 12 (1%) | 9 (1%) |
| Adverse Reactions | XYZAL 5 mg (n = 243) | Placebo (n = 240) |
| Pyrexia | 10 (4%) | 5 (2%) |
| Cough | 8 (3%) | 2 (<1%) |
| Somnolence | 7 (3%) | 1 (<1%) |
| Epistaxis | 6 (2%) | 1 (<1%) |
| Adverse Reactions | XYZAL 1.25 mg Twice Daily (n = 114) | Placebo (n = 59) |
| Pyrexia | 5 (4%) | 1 (2%) |
| Diarrhea | 4 (4%) | 2 (3%) |
| Vomiting | 4 (4%) | 2 (3%) |
| Otitis Media | 3 (3%) | 0 (0%) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. In animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the oral route to pregnant rats and rabbits, during the period of organogenesis, at doses up to 390 times and 470 times, respectively, the maximum recommended human dose (MRHD) in adults.
In rats treated during late gestation and the lactation period, cetirizine had no effects on pup development at oral doses up to approximately 60 times the MRHD in adults. In mice treated during late gestation and the lactation period, cetirizine administered by the oral route to the dams had no effects on pup development at a dose that was approximately 25 times the MRHD in adults; however, lower pup weight gain during lactation was observed at a dose that was 95 times the MRHD in adults [see Data].
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal data In embryo-fetal development studies, pregnant rats received daily doses of levocetirizine up to 200 mg/kg/day from gestation days 6 to 15 and pregnant rabbits received daily doses of levocetirizine up to 120 mg/kg/day from gestation days 6 to 18. Levocetirizine produced no evidence of fetal harm in rats and rabbits at doses up to 390 and 470 times the MRHD, respectively (on a mg/m 2 basis with maternal oral doses of 200 and 120 mg/kg/day in rats and rabbits, respectively).
No prenatal and postnatal development (PPND) studies in animals have been conducted with levocetirizine. In a PPND study conducted in mice, cetirizine was administered at oral doses up to 96 mg/kg/day from gestation day 15 through lactation day 21. Cetirizine lowered pup body weight gain during lactation at an oral dose in dams that was approximately 95 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 96 mg/kg/day); however, there were no effects on pup weight gain at an oral dose in dams that was approximately 25 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 24 mg/kg/day).
In a PPND study conducted in rats, cetirizine was administered at oral doses up to 180 mg/kg/day from gestation day 17 to lactation day 22. Cetirizine did not have any adverse effects on rat dams or offspring development at doses up to approximately 60 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 30 mg/kg/day).
Cetirizine caused excessive maternal toxicity at an oral dose in dams that was approximately 350 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 180 mg/kg/day).
Mechanism of action
12.1 Mechanism of Action Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H 1 -receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). The clinical relevance of this finding is unknown.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Studies in adult healthy subjects showed that levocetirizine at doses of 2.5 mg and 5 mg inhibited the skin wheal and flare caused by the intradermal injection of histamine. In contrast, dextrocetirizine exhibited no clear change in the inhibition of the wheal and flare reaction. Levocetirizine at a dose of 5 mg inhibited the wheal and flare caused by intradermal injection of histamine in 14 pediatric subjects (aged 6 to 11 years) and the activity persisted for at least 24 hours.
The clinical relevance of histamine wheal skin testing is unknown. A QT/QTc study using a single dose of 30 mg of levocetirizine did not demonstrate an effect on the QTc interval. While a single dose of levocetirizine had no effect, the effects of levocetirizine may not be at steady state following single dose. The effect of levocetirizine on the QTc interval following multiple dose administration is unknown.
Levocetirizine is not expected to have QT/QTc effects because of the results of QTc studies with cetirizine and the long postmarketing history of cetirizine without reports of QT prolongation.
Pharmacokinetics
Elimination The plasma half-life in adult healthy subjects was about 8 to 9 hours after administration of oral tablets and oral solution, and the mean oral total body clearance for levocetirizine was approximately 0.63 mL/kg/min.
The major route of excretion of levocetirizine and its metabolites is via urine, accounting for a mean of 85.4% of the dose.
Excretion via feces accounts for only 12.9% of the dose.
Levocetirizine is excreted both by glomerular filtration and active tubular secretion.
Renal clearance of levocetirizine correlates with that of creatinine clearance.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Levocetirizine exhibited linear pharmacokinetics over the therapeutic dose range in adult healthy subjects. Absorption Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 hour after administration of the oral tablet.
The accumulation ratio following daily oral administration is 1.12 with steady state achieved after 2 days. Peak concentrations are typically 270 ng/mL and 308 ng/mL following a single and a repeated 5 mg once daily dose, respectively. Food had no effect on the extent of exposure (AUC) of the levocetirizine tablet, but T max was delayed by about 1.25 hours and C max was decreased by about 36% after administration with a high fat meal; therefore, levocetirizine can be administered with or without food.
A dose of 5 mg (10 mL) of XYZAL oral solution is bioequivalent to a 5 mg dose of XYZAL tablets. Following oral administration of a 5 mg dose of XYZAL oral solution to healthy adult subjects, the mean peak plasma concentrations were achieved approximately 0.5 hour post dose. Distribution The mean plasma protein binding of levocetirizine in vitro ranged from 91 to 92%, independent of concentration in the range of 90-5000 ng/mL, which includes the therapeutic plasma levels observed.
Following oral dosing, the average apparent volume of distribution is approximately 0.4 L/kg, representative of distribution in total body water. Metabolism The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of hepatic drug metabolizing enzyme inhibitors are expected to be negligible.
Metabolic pathways include aromatic oxidation, N- and O-dealkylation, and taurine conjugation. Dealkylation pathways are primarily mediated by CYP3A4 while aromatic oxidation involves multiple and/or unidentified CYP isoforms. Elimination The plasma half-life in adult healthy subjects was about 8 to 9 hours after administration of oral tablets and oral solution, and the mean oral total body clearance for levocetirizine was approximately 0.63 mL/kg/min.
The major route of excretion of levocetirizine and its metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via feces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion. Renal clearance of levocetirizine correlates with that of creatinine clearance.
In patients with renal impairment the clearance of levocetirizine is reduced [see Dosage and Administration (2.2)]. Drug Interaction Studies In vitro data on metabolite interaction indicate that levocetirizine is unlikely to produce, or be subject to metabolic interactions. Levocetirizine at concentrations well above C max level achieved within the therapeutic dose ranges is not an inhibitor of CYP isoenzymes 1A2, 2C9, 2C19, 2A1, 2D6, 2E1, and 3A4, and is not an inducer of UGT1A or CYP isoenzymes 1A2, 2C9 and 3A4.
No formal in vivo drug interaction studies have been performed with levocetirizine. Studies have been performed with the racemic cetirizine [see Drug Interactions (7)]. Pediatric patients Data from a pediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that C max and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison.
The mean C max was 450 ng/mL, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this pediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in pediatric patients younger than 6 years of age.
A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age results in plasma concentrations similar to those of adults receiving 5 mg once daily.
Geriatric patients Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65-74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age.
This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the XYZAL dose should be adjusted in accordance with renal function in elderly patients [see Dosage and Administration (2)]. Gender Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender.
The half-life was slightly shorter in women (7.08 ± 1.72 hr) than in men (8.62 ± 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 ± 0.16 mL/min/kg) appears to be comparable to that in men (0.59 ± 0.12 mL/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.
Race The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.
Renal impairment Levocetirizine exposure (AUC) exhibited 1.8-, 3.2-, 4.3-, and 5.7-fold increase in mild, moderate, severe, renal impaired, and end-stage renal disease patients, respectively, compared to healthy subjects. The corresponding increases of half-life estimates were 1.4-, 2.0-, 2.9-, and 4-fold, respectively.
The total body clearance of levocetirizine after oral dosing was correlated to the creatinine clearance and was progressively reduced based on severity of renal impairment. Therefore, it is recommended to adjust the dose and dosing intervals of levocetirizine based on creatinine clearance in patients with mild, moderate, or severe renal impairment.
In end-stage renal disease patients (CL CR < 10 mL/min) levocetirizine is contraindicated. The amount of levocetirizine removed during a standard 4-hour hemodialysis procedure was <10%. The dosage of XYZAL should be reduced in patients with mild renal impairment. Both the dosage and frequency of administration should be reduced in patients with moderate or severe renal impairment [see Dosage and Administration (2.2)].
Hepatic impairment XYZAL has not been studied in patients with hepatic impairment. The non-renal clearance (indicative of hepatic contribution) was found to constitute about 28% of the total body clearance in healthy adult subjects after oral administration. As levocetirizine is mainly excreted unchanged by the kidney, it is unlikely that the clearance of levocetirizine is significantly decreased in patients with solely hepatic impairment [see Dosage and Administration (2)].
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Xyzal · Chattem, Inc. [US FDA-approved label, version 2, July 22, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1673f7ff-0c7c-4403-86cf-c05eb1475222
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .